These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2798988)

  • 1. [Systemic cardiorespiratory effects induced by doxofylline].
    Bagnato GF; Allegra A; De Leo A; Giacobbe MS; Mileto A; Cinquegrani M; Leotta G; Buemi AL; Spina E; Scibilia M
    Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):29-35. PubMed ID: 2798988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial.
    Melillo G; Balzano G; Jodice F; De Felice A; Campisi V; Capone M; Di Filippo A; Foddai G; Franzone JS; Grossi E
    Int J Clin Pharmacol Res; 1989; 9(6):397-405. PubMed ID: 2699466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of moderate chronic obstructive pulmonary disease (stable) with doxofylline compared with slow release theophylline--a multicentre trial.
    Santra CK
    J Indian Med Assoc; 2008 Dec; 106(12):791-2, 794. PubMed ID: 19370950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of doxofylline sachets in a pediatric population].
    Bagnato G; Fodale P; Bottari M
    Riv Eur Sci Med Farmacol; 1989 Aug; 11(4):359-63. PubMed ID: 2701030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial.
    Goldstein MF; Chervinsky P
    Med Sci Monit; 2002 Apr; 8(4):CR297-304. PubMed ID: 11951074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of theophylline and doxofylline on airway responsiveness in beagles].
    Sugeta A; Imai T; Idaira K; Horikoshi S; Okamoto M; Adachi M
    Arerugi; 1997 Jan; 46(1):7-15. PubMed ID: 9078607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease.
    Shukla D; Chakraborty S; Singh S; Mishra B
    Expert Opin Pharmacother; 2009 Oct; 10(14):2343-56. PubMed ID: 19678793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxofylline, an adenosine-nonblocking xanthine, does not induce cardiostimulant effects.
    Cirillo R; Grossi E; Franzone JS
    Res Commun Chem Pathol Pharmacol; 1989 Jul; 65(1):21-34. PubMed ID: 2781149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals.
    Franzone JS; Cirillo R; Barone D
    Drugs Exp Clin Res; 1988; 14(7):479-89. PubMed ID: 3240706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxofylline in rat brain in relation to locomotor activity.
    Cravanzola C; Reboani MC; Grosa G; Franzone JS
    Drug Metab Dispos; 1989; 17(4):437-40. PubMed ID: 2571486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral doxophylline in patients with chronic obstructive pulmonary disease.
    Villani F; De Maria P; Ronchi E; Galimberti M
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):107-11. PubMed ID: 9088999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease.
    Lal D; Manocha S; Ray A; Vijayan VK; Kumar R
    J Basic Clin Physiol Pharmacol; 2015 Sep; 26(5):443-51. PubMed ID: 25894641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effectiveness and safety of a controlled-release theophylline in patients with reversible and stable bronchial obstruction.
    Grassi V; Nicora M; Beretta A
    Int J Clin Pharmacol Res; 1987; 7(5):337-44. PubMed ID: 3667006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis.
    Cogo R; Castronuovo A
    Eur Rev Med Pharmacol Sci; 2000; 4(1-2):15-20. PubMed ID: 11409184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of doxofylline in COPD: A pairwise meta-analysis.
    Cazzola M; Calzetta L; Rogliani P; Page C; Matera MG
    Pulm Pharmacol Ther; 2018 Aug; 51():1-9. PubMed ID: 29705620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma.
    Bagnato GF
    Eur Rev Med Pharmacol Sci; 1999; 3(6):255-60. PubMed ID: 11261736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: double-blind placebo-controlled clinical trial of doxofylline versus theophylline and bamifylline.
    Dini FL; Pasini G; Cortellini G; Cani E; Bettini R; Garagnani A; Gobbi G; Greco A; Onorato G; Pasini P
    Int J Clin Pharmacol Res; 1993; 13(6):305-16. PubMed ID: 8088931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravenously administered doxofylline and placebo for the treatment of severe acute airways obstruction.
    Dolcetti A; Osella D; De Filippis G; Carnuccio C; Grossi E
    J Int Med Res; 1988; 16(4):264-9. PubMed ID: 3169372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes.
    Talmon M; Massara E; Brunini C; Fresu LG
    Pulm Pharmacol Ther; 2019 Dec; 59():101851. PubMed ID: 31563516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of buprenorphine on cardiovascular and pulmonary function in clinically normal horses and horses with chronic obstructive pulmonary disease.
    Szöke MO; Blais D; Cuvelliez SG; Lavoie JP
    Am J Vet Res; 1998 Oct; 59(10):1287-91. PubMed ID: 9781463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.